Viessmann invests in schülke driving sustainable health protection for generations to come

In line with its purpose of co-creating living spaces for generations to come, the Viessmann family company continues the expansion of its ecosystem by becoming a new investor in schülke.

June 13, 2024 – The Viessmann Generations Group (“Viessmann”), a leading purpose-driven family company with a heritage of 107 years, today announced that it has acquired a significant minority stake in schülke, the sustainability leader in infection prevention and treatment for the healthcare and life sciences industries. With the investment, Viessmann joins the shareholder consortium led by the Munich-based single family office ATHOS and Bitburger Holding.

Boris Scukanec Hopinski, COO of Viessmann: “schülke is a pioneer in the prevention of infectious diseases, which pose an ever-increasing health risk for future generations due to the increasing spread of pathogenic bacteria and virus vectors. Setting new sustainability and innovation standards in the healthcare industry, schülke contributes directly to our purpose of co-creating living space for generations to come. By joining schülke’s shareholder consortium, we provide our expertise to optimally support the company’s mission of protecting lives worldwide.”    

Following the recent investment in the leading renewable energy platform Encavis, the strategic partnership with schülke marks a further step in Viessmann’s expansion of its broad range of activities to maximize the positive impact of the family company. Building on its heritage – the decarbonization of the building sector – through the generation and provision of renewable energies and clean air and water as well as the supply of food, Viessmann is amplifying its ecosystem with dedicated co-investments, and acquisitions – from early-stage investments, to investments in family-owned and public companies, to philanthropic engagements worldwide.  

Entering the health industry by acquiring a stake in schülke underlines the company’s holistic approach. With almost 135 years of tradition, schülke has established itself as an innovation leader and central partner to the healthcare sector in the development of holistic and system-critical solutions for infection prevention and treatment. As a leading provider of sustainable solutions, the company meets the  diverse needs of its customers, which include hospitals and other healthcare facilities, with high-quality products and high delivery reliability. In addition, the company sells its products to pharmacies and care providers as well as to the global life sciences industry. schülke holds market-leading positions in Central and Eastern Europe, Australia, and Brazil.

About Viessmann  

Founded in 1917, the independent family company Viessmann is today a global, broadly diversified Group. All activities are based on the company’s purpose "We co-create living spaces for generations to come”. This is the passion and responsibility that the large worldwide Viessmann family brings to life every day. Viessmann forms an ecosystem of entrepreneurs and co-creators with a clear focus on CO₂ avoidance, CO₂ reduction and CO₂ capturing.

About schülke

Schülke & Mayr GmbH, with its headquarters in Norderstedt near Hamburg, has been a global leader in infection prevention and control for almost 135 years. Infectious germs know no borders - this has always been the case and is even more common in today's globalized world. Committed to the mission "We protect lives worldwide", the strategic business areas of schülke Healthcare, Over the Counter (OTC) and Life Sciences actively contribute to the safety and health protection of people. With strong brands such as octenisept®, kodan®, desderman® or microshield®, schülke is one of the international market leaders in the field of wound and mucous membrane antisepsis as well as hand and surface disinfection in German hospitals. People in more than 80 countries around the world rely on schülke products every day. With its wide range of high-quality and innovative products, expert advice and reliable service, schülke offers holistic concepts for infection treatment and control in professional healthcare, for end users and the pharmaceutical sector. Schülke consists of more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). In 2022, schülke contributed to protecting patients and health care professionals in hospitals from infections with nearly three billion product applications.

You can find more information about schülke here:

Press Contact:

Byung-Hun Park
Vice President Corporate Communications
M: +49151-64911317